Cargando…
Serum biomarkers to predict clinical response in proof-of-concept trials in spondyloarthritis
Autores principales: | Turina, Maureen, Yeremenko, Nataliya, Paramarta, Jacqueline, Vandooren, Bernard, Tak, Paul Peter, De Rycke, Leen, Baeten, Dominique |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3242265/ http://dx.doi.org/10.1186/1479-5876-9-S2-P37 |
Ejemplares similares
-
Calprotectin (S100A8/9) as serum biomarker for clinical response in proof-of-concept trials in axial and peripheral spondyloarthritis
por: Turina, Maureen C, et al.
Publicado: (2014) -
A proof-of-concept study with the tyrosine kinase inhibitor nilotinib in spondyloarthritis
por: Paramarta, Jacqueline E., et al.
Publicado: (2016) -
Synovial Tissue Response to Treatment with TNF Blockers in Peripheral Spondyloarthritis
por: Paramarta, Jacqueline E, et al.
Publicado: (2011) -
IL-17 producing mast cells contribute to synovial inflammation in non-psoriatic and psoriatic spondyloarthritis
por: Noordenbos, Troy, et al.
Publicado: (2011) -
Serum inflammatory biomarkers fail to identify early axial spondyloarthritis: results from the SpondyloArthritis Caught Early (SPACE) cohort
por: Turina, Maureen C, et al.
Publicado: (2017)